September 2014
Issue 69
Kerri Sparling ( discusses CGM in the Cloud, explaining what it is and how it works. Sparling writes about its benefits and drawbacks that are leading to a split in the diabetes community - some people are celebrating its attributes while others are keeping their distance. 


Abbott’s Freestyle Libre launches in Europe, a new obesity medication clears an FDA hurdle, and more!

The curious milestone of a diabetes anniversary. 

What are the most solvable problems in diabetes? 

Could Tidepool’s software change type 1 diabetes?

Will a combination of type 2 drugs prove significantly better than one alone?

(S)he said what?!?

Hoping for an oral insulin – but why stop there?

Syndicate content